RxDoctor Payments Data

Callie Pearson

Physician Assistant · Springfield, MONPI 1487024147

Payments from drug & device makers

$955in general payments, 2019–2025

Across 44 payments — averaging $21.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$240
  • Otsuka America Pharmaceutical, Inc.$179
  • AbbVie$141
  • Neurocrine Biosciences, Inc.$126
  • Axsome Therapeutics, Inc.$125
  • Sunovion Pharmaceuticals Inc.$52
  • plus $92 from 4 others

What the payments were for

  • Food & beverage$90895%
  • Education$475%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$955 in reported general payments places this provider in the 70th percentile of 1,380 physician assistant providers in Missouri.

See all physician assistant providers in Missouri

Medicare billing

Part B allowed, 2024
$20,957
Medicare patients
57
Services billed
210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl47$70,515
Invega SustennaPaliperidone Palmitate13$34,857
FanaptIloperidone12$21,805
TrintellixVortioxetine Hydrobromide19$12,811
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl54$9,406
Lurasidone Hcl38$5,918
Divalproex Sodium ErDivalproex Sodium26$2,531
Paliperidone ErPaliperidone15$2,362
Venlafaxine Hcl ErVenlafaxine Hcl120$2,270
Desvenlafaxine Succinate ErDesvenlafaxine Succinate30$2,243
Hydroxyzine Hcl123$2,221
Bupropion XlBupropion Hcl157$2,037
Quetiapine Fumarate120$2,006
Buspirone Hcl227$1,909
Vilazodone Hcl22$1,794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$141$70,51547 claims
Johnson & JohnsonInvega Sustenna$240$34,85713 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$12$12,81119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,380 physician assistant providers in Missouri.

Other physician assistant in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →